echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In order to support the development of new crown vaccines, Pfizer Q3 cuts off multiple research assets such as cancer vaccines and NASH

    In order to support the development of new crown vaccines, Pfizer Q3 cuts off multiple research assets such as cancer vaccines and NASH

    • Last Update: 2020-11-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    While all eyes are on Pfizer's COVID-19 vaccine research with BioNTech, a German biotech company, the big drugmaker has quietly "slimmed down" its research pipeline, eliminating two Phase 2 and one Phase 1 clinical trials.
    , Pfizer announced its third-quarter financial cuts on October 27th, in line with quarterly practice.
    The first phase of the study was the non-alcoholic fatty hepatitis 2 (NASH) drug PF-05221304, a candidate for acetyl coenzyme a carbohydrase inhibitor, which had previously been designated by the FDA as a fast-track and was undergoing a single-drug therapeutic clinical trial for patients with liver scarring.
    not say why it was eliminated, except for filing under "Stopped Items."
    PF-05221304 still appears to be active in trials used in a coalition with other drugs, but its future is likely to end up with major setbacks and failures, like most NASH drugs.
    second mid-term asset to be phased out is arthritis candidate drug PF-06650833, an IRAK4 inhibitor, which Pfizer did not disclose further details about.
    the end, the prostate cancer treatment vaccine PF-06753512, which is in clinical phase 1, has also been shelved, just as the fate of many other cancer vaccines has been met with promising scientific support, but has failed to meet expectations.
    in addition to three research projects, Pfizer has stopped clinical research projects on four listed drugs since July 28 this year, including two Phase 3 trials in which CDK4/6 kinase inhibitor Ibrace (palbociclib) treats high-risk early-stage breast cancer and smoothened (SMO) antagonists Daurismo (glasdegib) in combination with cytosine and erythromycin to treat acute myeloid leukemia; a Phase 2 trial to study Daurismo's treatment of bone marrow growth abnormal syndrome; and a Phase 1 trial for the biological study of anti-PD-L1 monoantigen Bavencio (avelumab) for cancer.
    the third quarter of this year, Pfizer had high hopes for a COVID vaccine program with BioNTech and was looking forward to releasing new data, but the big drugmaker is still waiting for results.
    Pfizer had previously said it could release early data as early as late October to see if the vaccine candidates were effective and possibly seek approval.
    but that deadline is about to pass.
    But more positive changes can be found from the latest information released by Pfizer on the 27th, compared with the end of July this year, the company's total assets in the pipeline projects reached 92, including 58 new molecular entities (NMEs), 33 approved drugs additional adaptive research and 1 biosylikes, registration and approval projects increased by two, phase 1 clinical projects increased by four.
    of these, six registered approved items were JAK1 inhibitor abrocitinib (PF-04965842) for the treatment of endemic dermatitis (prioritized and breakthrough therapy identified) (application for listing in the United States and the European Union); Chronic pain caused by arthritis (U.S. and European Union); Neulasta® biosimilar PF-06881894 treats leurial reduction in patients undergoing chemotherapy for cancer (EU); and androgen inhibitor Xtandi (enzalutamide) treats metastatic degenerative prostate cancer (EU); and Bavencio (avelumab) treats urethra cancer (EU).
    In addition, Pfizer had four new approved adaptations in the third quarter of this year, namely BAVENCIO® (avelumab) in combination with platinum-containing chemotherapy for the first-line maintenance treatment of unrealized localized advanced or metastatic urethra cancer (approved in the United States®®); Adult patients with brafV600E mutated metastatic colorectal cancer treated throughout the body (EU approved); Hedgehog pathway inhibitor DAURISMOTM (glasdegib) was used in combination with low-dose LDAC to treat adult patients with acute myeloid leukemia (EU approved) who were not suitable for new diagnosis (first or secondary) of standard chemotherapy(EU approved); and Neulasta® (pegfilgrastim) biosimilar NYVEPRIATM (pegfilgrastim-apgf) to reduce infections caused by bone marrow-inhibiting anti-cancer drugs in patients with non-bone marrow malignancies, such as fever-neutral granulocytosis (approved in the United States).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.